Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Saved in:

Bibliographic Details
Title:	Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Authors:	Burmester, Gerd¹ (AUTHOR) gerd.burmester@charite.de, Drescher, Edit² (AUTHOR), Hrycaj, Pawel³ (AUTHOR), Chien, David⁴ (AUTHOR), Pan, Zhiying⁴ (AUTHOR), Cohen, Stanley⁵ (AUTHOR)
Source:	Clinical Rheumatology. Nov2020, Vol. 39 Issue 11, p3341-3352. 12p.
Database:	Academic Search Ultimate

Description
ISSN:	07703198
DOI:	10.1007/s10067-020-05305-y